01—Abstract
Summary
Summary of the 8-K filed May 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) filed an 8-K on May 28, 2025 disclosing two board changes and a related press release.
The Board appointed Lori J. Ryerkerk as an independent director effective June 1, 2025. Ms. Ryerkerk is the former Chairman, President and CEO of Celanese and brings public-company CEO and global supply chain and manufacturing operations experience.
She has not yet been assigned to any Board committees, and her compensation will be pro-rated through the 2026 Annual Meeting of Stockholders. The filing also discloses the resignation of Ornella Barra, a director since 2015 who sat on the Finance Committee and the Compliance and Risk Committee. She resigned on May 27, 2025, effective immediately.
The company states her departure was not due to any disagreement over operations, policies or practices. The resignation is tied to Walgreens Boots Alliance (WBA) falling below 5%a ownership after the scheduled early-June settlement of prepaid variable share forward transactions. WBA does not currently intend to use its 5% stockholder right to designate a replacement, and once its stake drops below 5% it will lose the right to designate directors under the Amended and Restated Shareholders Agreement.
For investors, the filing is primarily governance-related and carries no disclosed financial impact. The notable signal is the reduction of WBA's influence over the Board, which removes a long-standing designation right tied to its large shareholding. The Ryerkerk appointment adds operational and supply chain expertise that management frames as supporting the company's end-to-end healthcare services strategy.
02—Key points
Key Highlights
- Lori J. Ryerkerk appointed as independent director effective June 1, 2025; no committee assignments yet and no related-party transactions disclosed.
- Ms. Ryerkerk is the former Chairman, President and CEO of Celanese, with prior experience including Executive Vice President of Global Manufacturing at Shell Downstream Inc. and current board seats at Eaton Corp. and Norfolk Southern.
- Ornella Barra resigned from the Board on May 27, 2025, effective immediately, after serving as a director since 2015 and sitting on the Finance and Compliance and Risk Committees.
- Barra's resignation is linked to WBA's stake falling below 5% following the early-June 2025 settlement of prepaid variable share forward transactions; the company says it was not a dispute over operations or policies.
- WBA does not currently plan to designate a replacement director and will lose its board designation rights once its ownership drops below 5% under the Shareholders Agreement.
- Ryerkerk's director compensation, including the annual equity award, is pro-rated from June 1, 2025 through the 2026 Annual Meeting of Stockholders.
- The filing reports no direct financial results or guidance; the press release describes Cencora as having more than $290 billion in annual revenue.
03—Questions
Frequently Asked Questions
Why did Ornella Barra resign from Cencora's Board?
The company says she resigned in anticipation of Walgreens Boots Alliance's ownership falling below 5% after the scheduled settlement of prepaid variable share forward transactions in early June 2025. Cencora states her resignation was not due to any disagreement with the company on operations, policies or practices.
Will Walgreens Boots Alliance still have a seat on the Board?
Not after this change. WBA has said it does not currently intend to use its 5% stockholder right to fill the vacancy. Under the Amended and Restated Shareholders Agreement, WBA will no longer be entitled to designate any directors once its ownership falls below 5%.
Who is Lori J. Ryerkerk and what does she bring to the Board?
She is the former Chairman, President and CEO of Celanese, where she led the company from 2019 to its CEO transition and became Chairman in 2020. Earlier she spent over 25 years in manufacturing operations leadership, including at Shell Downstream. The company cites her experience with complex global supply chains and operations as relevant to its healthcare services strategy.
Does this director change affect Cencora's financials or guidance?
The filing does not disclose any financial impact, earnings results, or guidance changes. It is a governance update covering board composition and director compensation terms.
Which committees will Ryerkerk serve on?
As of the filing, she has not been named to any Board committee. Committee assignments could be announced later, so investors should watch for a subsequent update.
04—Continue